2007
Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson D, Gilmor M, Yang Y, Moonsammy G, Azzaro A, Oren D, Campbell B. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials. Psychopharmacology Bulletin 2007, 40: 15-28. PMID: 18007565.Peer-Reviewed Original ResearchConceptsMontgomery-Asberg Depression Rating ScaleMajor depressive disorderDepression Rating ScaleHAM-D28Rating ScaleDepressive disorderEfficacy trialsIndividual symptomsTreatment effectsPlacebo-controlled efficacy trialTransdermal systemSelegiline transdermal systemEnd of treatmentHamilton Rating ScaleBeneficial therapeutic effectsMajor monoamine neurotransmittersMonoamine oxidase inhibitorsRandom-effects modelCore depression symptomsGenital symptomsMADRS itemsDrug therapySignificant treatment effectTherapeutic effectSpecific symptoms
2004
Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings.
Epperson CN, Terman M, Terman JS, Hanusa BH, Oren DA, Peindl KS, Wisner KL. Randomized clinical trial of bright light therapy for antepartum depression: preliminary findings. The Journal Of Clinical Psychiatry 2004, 65: 421-5. PMID: 15096083, DOI: 10.4088/jcp.v65n0319.Peer-Reviewed Original ResearchConceptsBright light therapyClinical trialsLight therapyAntepartum depressionDouble-blind placebo-controlled pilot studyPlacebo-controlled pilot studyRecent open-label studyDSM-IV major depressive disorderOpen-label studyAntidepressant drug trialsRandomized clinical trialsMajor depressive disorderAntidepressants resultsStructured interview guideActive treatmentClinical statusPregnant womenSuccessful treatmentDepressive disorderPlacebo lightDrug trialsPromising treatmentSalivary melatoninExtension phasePilot studyAddition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS. Addition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response. Neuropsychopharmacology 2004, 29: 1166-1171. PMID: 15010697, DOI: 10.1038/sj.npp.1300418.Peer-Reviewed Original ResearchConceptsHamilton depression scale ratingsΑ2-antagonist yohimbineAntidepressant responseClinical Global Impression ratingsBlood pressure changesPercentage of respondersLog-rank testGlobal Impression ratingsMajor depressive disorderMore rapid onsetP subjectsDSM-IV diagnosisSSRI agentsTitrated doseYohimbine doseAntidepressant actionAntidepressant medicationCGI scaleNoradrenergic toneMonoaminergic neurotransmissionΑ2-adrenoceptorsDepressive disorderTreatment periodOutcome measuresSCID interview
2002
Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research 2002, 113: 245-254. PMID: 12559481, DOI: 10.1016/s0165-1781(02)00267-6.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTreatment-resistant depressed patientsDepressed patientsTherapeutic effectActive repetitive transcranial magnetic stimulationStimulation parametersTreatment-resistant depressionDouble-blind designTranscranial magnetic stimulationLeft prefrontal cortexSham groupMagnetic stimulationStimulation courseRTMS stimulationPatientsSystematic followThreshold stimulationPrefrontal cortexFollowPre-set criteriaSignificant differencesStimulationWork daysWeeksConsecutive work daysAn Open Trial of Morning Light Therapy for Treatment of Antepartum Depression
Oren D, Wisner K, Spinelli M, Epperson C, Peindl K, Terman J, Terman M. An Open Trial of Morning Light Therapy for Treatment of Antepartum Depression. American Journal Of Psychiatry 2002, 159: 666-669. PMID: 11925310, DOI: 10.1176/appi.ajp.159.4.666.Peer-Reviewed Original ResearchConceptsWeeks of treatmentMorning light therapyBright light therapyLight therapyAntepartum depressionOpen trialMajor depressionMorning bright light therapyHamilton Depression Rating ScaleSeasonal Affective Disorder VersionDepression Rating ScaleNovel treatment approachesFollow-up questionnairePregnant patientsAntidepressant effectsPregnant womenDepression ratingsTreatment approachesTherapyRating ScaleAdverse effectsDepressionTrialsWeeksPregnancyMonoamine depletion in unmedicated depressed subjects
Berman RM, Sanacora G, Anand A, Roach LM, Fasula MK, Finkelstein CO, Wachen RM, Oren DA, Heninger GR, Charney DS. Monoamine depletion in unmedicated depressed subjects. Biological Psychiatry 2002, 51: 469-473. PMID: 11922881, DOI: 10.1016/s0006-3223(01)01285-9.Peer-Reviewed Original ResearchConceptsUnmedicated depressed subjectsDepressed subjectsCatecholamine depletionDepressed patientsMean Hamilton Depression Rating Scale scoreHamilton Depression Rating Scale scoresRandom-order crossover studyDepression Rating Scale scoresRating Scale scoresDepressed control subjectsSignificant mood changesMonoamine depletionCrossover studyCatecholamine functionControl subjectsMonoamine functionMonoamine systemsStudy daysClinical depressionScale scoreMood changesPatientsIndoleamineGreater increaseIndirect mechanisms
2000
No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects
Oren D, Berman R, Anand A, Charney D. No effect of light on basal glucagon levels in winter seasonal depressives and comparison subjects. Psychiatry Research 2000, 94: 263-266. PMID: 10889291, DOI: 10.1016/s0165-1781(00)00158-x.Peer-Reviewed Original ResearchMeSH KeywordsAdultDepressive Disorder, MajorFemaleGlucagonHumansMalePhototherapySeasonal Affective DisorderSeasonsTreatment OutcomeAntidepressant effects of ketamine in depressed patients
Berman R, Cappiello A, Anand A, Oren D, Heninger G, Charney D, Krystal J. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry 2000, 47: 351-354. PMID: 10686270, DOI: 10.1016/s0006-3223(99)00230-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsDepressive Disorder, MajorDose-Response Relationship, DrugDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleGlutamic AcidHumansInjections, IntravenousKetamineMaleMiddle AgedPsychiatric Status Rating ScalesReceptors, N-Methyl-D-AspartateSeverity of Illness IndexConceptsMajor depressionN-methyl-D-aspartate receptor antagonistBrain glutamate systemDouble-blind trialDouble-blind conditionsTreatment of depressionMechanism of actionPlacebo infusionAntidepressant effectsIntravenous treatmentSingle doseReceptor antagonistDepressed patientsGlutamate systemDepressive symptomsPreclinical researchKetamine hydrochlorideDepressionPotential roleTest dayTreatment effectsPatientsKetamineSaline solutionTreatment